Claims for Patent: 10,052,267
✉ Email this page to a colleague
Summary for Patent: 10,052,267
Title: | Topical glycopyrrolate formulations |
Abstract: | Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer. |
Inventor(s): | Johnston; Michael (Yarraville, AU), Houlden; Robert James (Kilsyth, AU) |
Assignee: | ROSE U, LLC (Palo Alto, CA) |
Application Number: | 15/662,166 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,052,267 |
Patent Claims: |
1. A glycopyrrolate solution comprising: about 0.5 to about 4.0% w/w of a glycopyrrolate compound having the following formula: ##STR00003## wherein X.sup.- is a
pharmaceutically acceptable counter ion salt; ethanol and water in a weight ratio of about 50:50 to about 60:40; a buffering agent, comprising an acid and a base, said acid and base at a total concentration of about 0.2 to about 0.5% w/w and at an
acid:base ratio sufficient to maintain a pH of the glycopyrrolate solution of about 3.5 to about 6 at 25.degree. C.; wherein the acid is citric acid and the base is selected from the group consisting of sodium citrate and tromethamine; wherein the
pharmaceutically acceptable counter salt is prepared from an inorganic or organic acid selected from hydrochloric acid, hydrobromic acid, hydrogen fluoride, hydrogen iodide, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid,
glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, and
salicylic acid.
2. The glycopyrrolate solution of claim 1, wherein the buffering agent maintains a pH of the solution of about 4 to about 5. 3. The glycopyrrolate solution of claim 1, wherein the buffering agent maintains a pH of the solution of about 4.5. 4. The glycopyrrolate solution of claim 1, wherein the glycopyrrolate compound degrades by less than 1% when stored at 0 to 25.degree. C. for at least one month, two months, six months or one year. 5. The glycopyrrolate solution of claim 1, wherein the ethanol to water weight ratio is about 60:40. 6. The glycopyrrolate solution of claim 1, wherein the ethanol is at about 53.7 to about 57.3% w/w, and the water is added to 100% w/w. 7. The glycopyrrolate solution of claim 1, wherein the pharmaceutically acceptable counter salt is prepared from hydrobromic acid. 8. The glycopyrrolate solution of claim 1, wherein the pharmaceutically acceptable counter salt is prepared from p-toluene-sulfonic acid. 9. The glycopyrrolate solution of claim 1, wherein the glycopyrrolate compound is about 2.0% w/w of the glycopyrrolate solution. 10. The glycopyrrolate solution of claim 1, wherein the glycopyrrolate compound is about 4.0% w/w of the glycopyrrolate solution. 11. The glycopyrrolate solution of claim 1, wherein the base is tromethamine. 12. The glycopyrrolate solution of claim 1, wherein the base is sodium citrate. 13. The glycopyrrolate solution of claim 1, further comprising propylene glycol. 14. The glycopyrrolate solution of claim 1, further comprising a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer. 15. The glycopyrrolate solution of claim 14, wherein the polymer system comprises a polyvinyl pyrrolidone and a butyl ester of polyvinylmethylether/maleic anhydride copolymer. 16. An individually packaged wipe for the treatment of hyperhidrosis comprising a wipe loaded with the glycopyrrolate solution of claim 1 contained within a pouch resistant to leakage. 17. The individually packaged wipe of claim 16, wherein the wipe is selected from the group consisting of nonwoven material, paper material, woven material, knitted material, tufted material, stitched-bonded material, and material felted by wet-milling material. 18. The individually packaged wipe of claim 16, wherein the pouch comprises an inner lining of linear low density polyethylene (LLDPE). 19. A method for alleviating hyperhidrosis in a mammal comprising the topical administration of the glycopyrrolate solution of claim 1 to an area of the body such that the hyperhidrosis is reduced. 20. A method for alleviating hyperhidrosis in a mammal comprising the topical administration of the wipe of claim 16, following removal from the pouch, to an area of the body such that the hyperhidrosis is reduced. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.